Ratification of the appointment of Mr. Jean-Pierre Garnier as a Director
CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer
of the world’s most advanced total artificial heart, aiming to provide a
therapeutic alternative for people suffering from end-stage
biventricular heart failure, informs its shareholders that the Mixed
Shareholders’ Meeting held on March 28, 2019 was able to deliberate,
quorum having been reached.
The Meeting approved all the resolutions tabled, with the exception of
the 29th resolution, which was rejected on the recommendation
of the Board of Directors.
The Company’s shareholders notably ratified the cooptation of Mr.
Jean-Pierre Garnier to the Board of Directors, enabling him to
effectively carry out his duties as Chairman of the Board, as announced
Moreover, Professor Alain Carpentier has become CARMAT’s Honorary
Chairman, his mandate as a Board member having expired due to him
reaching the age limit defined in the Company’s statutes.
The Board of Directors will thus consist of 9 members, 5 of them
Mr. Jean-Pierre Garnier, Director and Chairman of the Board
Mr. Stéphane Piat, Chief Executive Officer
Mr. Henri Lachmann, Independent Director
Santé Holdings S.R.L., represented by Dr. Antonino Ligresti,
Dr. Michael Mack, Independent Director
Mr. Pierre Bastid, Independent Director
Mr. Jean-Luc Lemercier, Independent Director
Truffle Capital, represented by Mr. Philippe Pouletty
Airbus Group, represented by Mrs. Anne-Pascale Guédon
CARMAT would like to thank all of the shareholders who attended in
person, were represented by proxy or who voted by post for their
commitment and support.
The consolidated result of the votes for each resolution and the minutes
of the Mixed Shareholders’ Meeting of March 28, 2019 will be made
available on the Company’s website, www.carmatsas.com,
in the Regulated Information section, within the statutory timeframe.
ISIN code: FR0010907956
This press release and the information contained herein do not
constitute an offer to sell or subscribe to, or a solicitation of an
offer to buy or subscribe to, shares in CARMAT ("the Company") in any
country. This press release contains forward‐looking statements that
relate to the Company’s objectives. Such forward‐looking statements are
based solely on the current expectations and assumptions of the
Company’s management and involve risk and uncertainties. Potential risks
and uncertainties include, without limitation, whether the Company will
be successful in implementing its strategies, whether there will be
continued growth in the relevant market and demand for the Company’s
products, new products or technological developments introduced by
competitors, and risks associated with managing growth. The Company’s
objectives as mentioned in this press release may not be achieved for
any of these reasons or due to other risks and uncertainties.
No guarantee can be given as to any of the events anticipated by the
forward-looking statements, which are subject to inherent risks,
including those described in the Document de Référence
registration document filed with the Autorité des Marchés Financiers
under number D.19-0135 on March 12, 2019, as well as changes in economic
conditions, the financial markets or the markets in which CARMAT
operates. In particular, no guarantee can be given concerning the
Company’s ability to finalize the development, validation and
industrialization of the prosthesis and the equipment required for its
use, to manufacture the prostheses, satisfy the requirements of the
ANSM, enroll patients, obtain satisfactory clinical results, perform the
clinical trials and tests required for CE marking and to obtain the CE
mark. CARMAT products are currently exclusively used within the
framework of clinical trials.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190328005973/en/